Integrated Wealth Concepts’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Integrated Wealth Concepts’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,171	Closed	-$1.14M	–	1644
2023 Q2	$1.14M	Sell	11,171 -123	-1%	-$11.6K	0.02%	623
2023 Q1	$1.03M	Buy	+11,294	New	+$663K	0.02%	604

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Integrated Wealth Concepts's RETA Position: Q3 2023 in Review

Integrated Wealth Concepts sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 11,171 shares — an estimated $1.14M sold.

Integrated Wealth Concepts first reported a position in RETA in Q1 2023 and held it in 2 quarters. The position peaked at $1.14M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Integrated Wealth Concepts reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Integrated Wealth Concepts sold 11,171 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.14M.
Integrated Wealth Concepts first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2023 and held it in 2 quarters.
Integrated Wealth Concepts's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.14M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Integrated Wealth Concepts's 13F filing for Q3 2023, filed 15 Nov 2023.